The Efficacy of Bisphosphonates in Preventing Aromatase Inhibitor Induced Bone Loss for Postmenopausal Women with Early Breast Cancer: A Systematic Review and Meta-Analysis
Table 2
Design and characteristics of trials included in the systematic review and metaanalysis.
Author (trial)
Year
Number of patients
Dosage of bisphosphonate
Combination therapy
Duration
Median follow up (months)
Intervention
Jadad score
Lombart et al. (E-ZO FAST)
2009
527
4 mg IV every 6 months
2.5 mg letrozole daily
5 years
36
Immediate ZOL 4 mg every 6 months, delayed ZOL 4 mg every 6 months